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ABSTRACT 
 
Purpose:  
This study examined the utility of sets of Single Nucleotide Polymorphisms (SNPs) in familial but 
non-BRCA-associated breast cancer (BC). 
 
Methods:  
We derived a polygenic risk score (PRS) based on 24 known BC risk SNPs for 4,365 women 
from the BCFR and kConFab familial BC cohorts. We compared scores in women based on 
cancer status at baseline. 2,599 women unaffected at enrollment were followed for an average 
of 7.4 years. Cox proportional hazards regression was used to analyze the association of PRS 
with BC risk. The BOADICEA risk prediction algorithm was used to measure risk based on 
family history alone.  
 
Results:  
The mean (SD) PRS baseline was 2.25 (0.35) for the affected and 2.17 (0.35) for unaffected 
women from combined cohorts (p<10-6). During follow-up, 205 BCs occurred. The hazard ratios 
for continuous PRS (per SD), and upper vs. lower quintiles were 1.38 (95% CI: 1.22-1.56) and 
3.18 (95% CI: 1.84-5.23) respectively. Based on their PRS-based predicted risk, management 
for up to 23% of women could be altered. 
 
Conclusion:  
Including BC-associated SNPs in risk assessment can provide more accurate risk prediction 
than family history alone and can influence recommendations for cancer screening and 
prevention modalities for high-risk women.  
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INTRODUCTION 
 
In the recent initiative towards “precision medicine” announced by the National Institutes of 
Health
1
, the use of genetic information for the identification of high-risk groups for targeted 
screening and/or prevention is gradually becoming part of routine medical care. Once limited to 
pathogenic mutations in high-risk genes such as BRCA1, BRCA2, p53, and the mismatch repair 
genes associated with Lynch Syndrome, the last decade has seen the identification of additional 
genes for which pathogenic variants are associated with perhaps two- to five-fold increased 
risks of cancer, as well as an ever-increasing set of common SNPs, each of which is associated 
with a relative risk of 1.05 to 1.3 of developing breast cancer2,3. Although these SNPs are not 
useful for risk prediction when considered individually, theoretical calculations indicate that a 
combined score based on genotypes at a large number of such loci could have substantial 
predictive value for risk stratification in the general population
4,5
, as well as in BRCA1 and 
BRCA2 carriers
6
. The combination of high-risk genes such as BRCA1 and BRCA2 and the 
known SNPs described above is estimated to explain less than half of the familial aggregation of 
breast cancer. This notwithstanding, such sets of SNPs may have clinically useful predictive 
power in the familial setting, due to the increased risk of breast cancer conferred by a woman’s 
family history alone. To date, there has only been a single study7 examining the utility of such 
SNP panels in the familial context, and none in a prospective fashion. Sawyer et al.7 looked at 
differences in a PRS based on 22 SNPs between BRCA1/2 carriers and BRCA1/2 negative 
women with breast cancer from a familial cancer clinic in Australia, and a set of controls. They 
found that non-carrier cases had a higher PRS than BRCA1/2 carriers and that a higher 
proportion of non-BRCA1/2 cases individuals with a PRS in the top quartile had breast cancer 
diagnosed before age 30 compared to the lowest quartile. The goal of the present study was to 
examine the utility of panels of SNPs in the context of familial breast cancer, where women are 
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already at elevated risk due to their family history and to determine if such SNP panels could 
stratify women into clinically useful risk groups. Currently, various advisory bodies have 
proposed guidelines for the use of magnetic resonance imaging (MRI) in addition to 
mammography for women at high risk. For example, the American Cancer Society8 proposes 
lifetime risk thresholds of 20 – 25% for MRI while the UK NICE guidelines9 use a threshold of 
30%. Here we examine women in families not known to have BRCA1/2 mutations from two 
different familial breast cancer resources – the Breast Cancer Family Registry (BCFR) cohort 
and the Kathleen Cuningham Consortium Foundation for Research into Familial Breast Cancer 
(kConFab). This study is novel in two ways: first, it examines women who are already at 
increased familial risk, and second it prospectively analyzes women who were unaffected at 
cohort enrollment.   
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MATERIALS AND METHODS 
 
SNP selection and genotyping 
BCFR  
For BCFR subjects, a total of 24 SNPs were successfully genotyped (Supplemental Table S1 
online). These correspond to the loci known to be associated with breast cancer at the start of 
the study and do not include the more recent loci discovered as part of the iCOGS analyses
2,3
. 
These SNPs were genotyped using a capture-based next generation sequencing method 
developed by one of us (A.M.) specifically for this study.  
 
kConFab 
In kConFab, SNPs were genotyped in two phases using two different technologies. In the first 
phase,18 SNPs were typed using iPLEX, and in the second phase, an additional 90 SNPs were 
typed using Fluidigm technology. In order to have comparable scores for the two data sets to 
allow a combined analysis, we chose 24 SNPs, which were either the same SNP or in complete 
or strong ( 9.02 R ) linkage disequilibrium (LD) with the SNP genotyped in BCFR. 
Supplemental Table S1 online shows the minor allele frequency and odds ratio (OR) for the 
SNPs genotyped in each cohort.  
 
Subjects 
The BCFR is a National Cancer Institute sponsored resource of familial breast cancer 
(www.bcfamilyregistry.org )
10,11. It consists of over 15000 families enrolled since 1995 from six 
sites in the U.S. (Utah, Northern California, New York, Philadelphia), Australia, and Canada, 
with data collection on lifestyle factors, tumor histopathology, and increasingly, genetic 
information. Three of the sites incorporated a clinic-based ascertainment strategy, while the 
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other three were population-based. Recruitment and genetic studies were approved by the 
University of Utah IRB, and the local IRBs of the BCFR centers from which we received blood 
samples and data. Written informed consent was obtained from each participant. Families were 
selected for this study on the basis of availability of DNA samples in the family and age (at least 
one woman diagnosed with BC under age 60 years prior to enrollment and one or more 
unaffected women over age 30 years at baseline with a DNA sample available). In total, 2,467 
women were successfully genotyped for at least 20 of the 24 SNPs; of these, 96% had at least 
22 valid genotypes called. After exclusion of 376 women without the required dates of birth, 
enrollment, and follow-up end-points, 2,091 women from 707 families were included in the 
analyses.  Of these, 991 women in 481 families who were unaffected with BC and were less 
than 70 years of age at baseline were included in the prospective analyses. 
 
The second data set analyzed as part of this project was based on the kConFab
12
 resource that 
has enrolled BC families since 1997 and systematically followed up women every 3 years.13 
Details on the resource and the ascertainment criteria have been described elsewhere 
(www.kconfab.org). Subjects were selected for genotyping based solely on their phenotype at 
baseline, without regard for any subsequent cancers. For this study, eligibility was restricted to 
families with at least one family member genotyped for the SNPs of interest. Families were 
systematically screened for and excluded if found to contain a mutation in BRCA1, BRCA2, 
PALB2 or ATM. In this study we included 2,732 women from 535 families who had sufficient 
genotype data to compute PRS. After excluding women who did not meet the inclusion criteria, 
there were 2,274 women from 523 families eligible for analysis. Of these, 1,608 women from 
488 families were included in the prospective cohort based on the same inclusion criteria as for 
BCFR described above. All participants in this study signed informed consent and the study was 
approved by the Human Research Ethics Committee of the Peter MacCallum Cancer Center, as 
well as at all participating centers.  
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Statistical Methods 
Calculation of PRS 
We created a PRS for each genotyped individual based on their genotypes at each of the 24 
loci, defined for the thj  individual as  
24
1
)ln(
i iijj
RnPRS , where ijn  is the number of risk 
alleles carried by the thj  individual at the thi  SNP, }2,1,0{ijn  and iR  is the per-allele Relative 
Risk (estimated by the per allele Odds Ratio (OR) in Europeans from large published studies3) 
associated with the thi  SNP.  When SNP genotypes were missing for an individual (maximum of 
four missing genotypes per individual), they were included in the overall PRS by weighting each 
genotype by its expectation given the MAF at that locus and their relatives’ genotypes (if any) as 
estkiamted from 10,000 replicates of the data set using the simulation program SLINK14.  
 
For the 24 SNPs used here, the theoretical expected value of the PRS is 2.123 with variance of 
0.117, based on the ORs and MAF for each SNP. 
Assessment of family history 
As part of the Prof-SC cohort11 the BOADICEA model15 was used to predict BC risk in over 
18,000 unaffected women from the BCFR and KConFab cohorts. Although originally designed 
to predict probabilities of an individual carrying a BRCA1 or BRCA2 mutation, BOADICEA also 
predicts a woman’s risk of breast and ovarian cancer both for the next 10 years and until age 80 
(remaining lifetime risk) and has shown to an accurate predictor of breast cancer risk in a 
prospective study16. Specifically we used the predicted 10-year risk of BC as calculated by 
BOADICEA as a summary measure of each woman’s familial risk given her age and the 
ages/age at diagnosis and cancer (breast, ovarian, prostate and pancreatic) status of all their 
relatives and incorporates any available BRCA1/2 genetic testing results. Of the 2,599 women 
in the prospective analysis, BOADICEA scores were available for 2457 (95%) women. Lastly, 
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we used the BOADICEA remaining lifetime risk as a baseline for modification by PRS as 
described below to examine lifetime risk changes as a function of the SNP-based PRS.  
 
Statistical Analysis of PRS scores 
We compared PRS scores in women who were affected and unaffected with BC at entry into the 
into the BCFR or kConFab cohorts, In this analysis, all women with a PRS were included 
without regard to previous history of other cancers (e.g., ovarian cancer). To adjust for the slight 
differences in the specific SNPs used in the two cohorts and to express the estimated hazard 
ratios (HRs) per standard deviation, we normalized the PRS scores by subtracting the 
theoretical mean from each score and dividing by the theoretical standard deviation prior to 
analysis. The primary analyses were prospective in which women who were unaffected by BC 
and who had not undergone bilateral prophylactic mastectomy (BPM) prior to cohort enrolment 
were eligible for follow-up with the primary endpoint development of invasive BC or DCIS during 
the follow-up period. Women were censored at the earliest of 1) diagnosis of BC (invasive or 
DCIS); 2) BPM; 3) death; or 4) last follow-up questionnaire (or last date known to be alive and 
cancer free). The characteristics of the 2,599 women who form the prospective cohort are 
presented in Table 1. We used Cox proportional hazards models to evaluate the effect of PRS 
on BC risk in this cohort. In these analyses, we used both the continuous PRS score as an 
independent predictor as well as a comparison of the upper and lower quintile of such scores 
(calculated separately for BCFR and kConFab cohorts). The main analyses were stratified by 
study center (the six BCFR sites and kConFab) and all analyses used a robust variance 
estimator based on family membership to adjust the variance for correlations in scores and 
overall cancer risks in related individuals. Interactions with family history, age, and study center 
were done using multivariable Cox models including main effects and an interaction term.  
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In order to examine the effect of the PRS on the estimated lifetime risk of breast cancer as 
assessed by BOADICEA ( BLR ) we estimated a SNP-based cumulative risk for each woman in 
the sample by )*exp(1 iB HRLR  where )*exp( ii PRSHR   and   is the natural logarithm 
of the estimated HR for continuous PRS in the prospective cohort and iPRS  is the standardized 
PRS for the thi  woman in the cohort.  
 
All statistical analyses were done using STATA 12.0 (StataCorp, College Station TX).  
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RESULTS 
 
We first compared the PRS in all subjects at baseline. A total of 1,496 women affected with 
breast cancer (1,084 BCFR; 412 kConFab) and 2,869 (1,007 BCFR; 1,862 kConFab) 
unaffected women were available for analysis. There were highly significant differences 
between the mean PRS in affected women at baseline compared to unaffected women in each 
cohort as well as the combined set (p=3x10-5, 1x10-6, and1x10-10, respectively). The mean PRS 
in unaffected women of 2.170 is slightly higher than the theoretical mean of 2.123, which is 
expected given their selection from a positive family history. PRS scores were quite comparable 
between the two cohorts, especially in unaffected women. Table 1 shows the characteristics of 
the prospective cohort. The overall breast cancer incidence was higher in the BCFR cohort 
(p=0.0012) but this is likely because women in the BCFR were on average older at start of 
follow-up than those in kConFab (46.4 vs. 42.6; p<10-5) and may have had a less stringent 
family history criterion for entry than that for the BCFR. The results of the Cox proportional 
hazards models in the analysis of prospective data are shown in Table 2. In both of the cohorts 
and for both the continuous and upper vs. lower quintile PRS score, the PRS was associated 
with highly significant increased risk with a HR for upper vs. lower quintile of 3.18. HRs by 
quintile, for each study are shown in Supplemental Table S2 online. The HRs for the continuous 
PRS were not significantly different between the BCFR and kConFab study cohorts (p=0.13) for 
study*PRS interaction, but were borderline significant for the upper vs. lower quintile (P=0.05), 
nor did the HR vary significantly as a function of age at baseline (p=0.88 and p=0.71 for the two 
cohorts, respectively). We tested the validity of the proportional hazards assumption implicit in 
the Cox models; neither the quintiles defined by PRS (p=0.85) nor the continuous PRS score 
(p=0.64) showed departure from the proportional hazards assumption. In a sensitivity analyses 
we excluded women who had been affected with any cancer at baseline (including ovarian) and 
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censored women at date of diagnosis of any non-breast cancer occurring during follow-up. 
Results were only slightly changed from those above.  
We used Kaplan-Meier survival analysis to look at the cumulative risks of BC for the lower 
quintile, three middle quintiles, and upper quintile as shown in Figure 1. Risks to age 70 were 
51% (95% CI: 42% - 60%) for women in the highest quintile of PRS compared to 21% (14% - 
31%) in the lowest. Similar plots for each of the two cohorts individually are presented in 
Supplemental Figure S1 online.  
 
Analysis of PRS and family history 
In order to explore the joint relationship of the PRS and family history on risk, we added the 
BOADICEA 10-year risk score to the Cox models and looked at the effect of the PRS score 
adjusted for family history.  For the set of individuals with these scores, the HR associated with 
the PRS in the combined dataset was  1.36 (p=2x10-6) while with the BOADICEA 10-year score 
in the model the HR was only slightly reduced (1.34 (p=1x10-5)). The BOADICEA 10-year risk 
estimate was also a significant predictor (HR=1.1; p=9x10-4) of BC risk. There was no evidence 
of an interaction between the PRS and BOADICEA 10-year risk (p=0.31). Supplemental Figure 
S2 online shows the Kaplan-Meier plots for the lowest, middle, and highest tertiles of the 
baseline BOADICEA 10-year risk.  
 
Figure 2 displays a plot of the BOADICEA lifetime risk plotted against the estimated remaining 
lifetime risk based on the BOADICEA score and the individual PRS with indicators of the 20% 
and 25% risk categories which would be considered cutoffs for recommending screening breast 
MRI. Table 3 shows the numbers of women in each of the risk quadrants for the two thresholds. 
For example, assuming the 20% threshold for MRI screening, 249 women out of 1,585 (16%) 
moved from below the threshold to above this threshold.  
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DISCUSSION  
 
The results of this study show that using even a subset of the current ~96 breast cancer-
associated SNPs can provide a potentially useful stratification of women into risk groups. 
However, the SNPs that we did not include in our study are, in general rarer, and/or have 
smaller effect size so we believe we have captured a significant proportion of the known genetic 
variance of BC due to common alleles of small effect. Based on the theoretical standard 
deviation of the score calculated from 77 SNPs in Mavaddat et al.5 We calculate that our PRS 
score captures about 2/3 of the genetic variance represented in the more recent panel. It is 
likely that inclusion of more complete sets of SNPs would further increase the discriminatory 
power. To our knowledge this is the first prospective study (familial or otherwise) to demonstrate 
the ability of such SNP panels to predict breast cancer outcome. Sawyer et al.7 estimated an HR 
of 2.08 for the lowest quartile compared to the highest quartile in assessing the risk of 
contralateral BC using a PRS based on 22 SNPs. However, this was a retrospective analysis in 
which women who presented with bilateral BC were compared with unilateral cases. This 
compares with the HR of 3.18 for highest and lowest quintile in our prospective analysis based 
on a PRS composed of 24 SNPs. Comparing familial BC cases to controls, the Sawyer study 
found an Area Under the Curve (AUC) of 0.64 for predicting BC based on their PRS; in our 
prospective analysis we found an AUC of 0.59 (95% CI 0.55 - 0.63). The absolute risks 
associated with women in the highest quintile of PRS were quite high, but it must be noted that 
these women in the BCFR were selected for genotyping based on having a family history, and 
women/families enrolled in kConFab are selected on the basis of their family history.  
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Both the American Cancer Society8 and the National Comprehensive Cancer Network17 
guidelines propose that women with a lifetime risk for BC above 20 to 25% should receive MRI 
screening. Using the BOADICEA algorithm to predict lifetime risk and assuming the 25% 
threshold, 14% of women in this familial cohort would theoretically have a change in 
management (i.e., screening or prevention recommendations); with the lower threshold of 20%, 
this figure increases to 23%. However, these estimates are based on the HRs for the PRS 
estimated from the data and thus would not be, strictly speaking, valid estimates of risk and are 
specific to the risk distribution in this set of selected families. However, this does demonstrate 
how the PRS can be used to more effectively target screening/prevention choices in BRCA1/2-
negative women with a family history of the BC.  
 
In summary, we have shown that SNP panels can be a useful adjunct to genetic testing for high 
penetrance genes in women with a family history of BC. Inclusion of risk scores based on BC 
associated SNPs in risk assessment can provide more accurate risk prediction than family 
history alone and can influence recommendations for cancer screening and prevention 
modalities for high-risk women. 
 
Supplementary information is available at the Genetics in Medicine website. 
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Figure Legends: 
Figure 1. Kaplan-Meier plot of breast cancer risk in the prospective cohort for the upper, middle 
three, and lower quintiles of the PRS. P-value shown corresponds to log-rank test comparing 
the three curves.  
Figure 2. Scatter plot of BOADICEA lifetime risk against estimated lifetime risk based on the 
combination of BOADICEA score and the individual PRS. In the bottom panel solid horizontal 
and vertical line indicate the 20% threshold of lifetime risk while dashed lines denote the 25% 
threshold. Each red dot corresponds to an individual woman in the prospective cohort. Those in 
the upper left and lower right quadrants would be those who potentially could have a change in 
screening recommendations based on current guidelines.  
 
 
